Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės
PUMA-ALI-1201
Phase 2 small_molecule active
Quick answer
Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės for Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC) is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active